Lipolytic actions of secretin in mouse adipocytes by Chow, BKC & SEKAR, R
190 Journal of Lipid Research Volume 55, 2014
Copyright © 2014 by the American Society for Biochemistry and Molecular Biology, Inc.
This article is available online at http://www.jlr.org
could lead to lipotoxicity, which is associated with condi-
tions such as obesity and insulin resistance ( 4, 5 ). 
 Among the hormones involved in the regulation of 
lipolysis, catecholamines and insulin are two well-recog-
nized factors. Catecholamines via circulation or sympa-
thetic innervations either stimulate lipolysis through the 
  -adrenergic receptor or exert anti-lipolytic activity by 
binding to the G  i-coupled   -2 adrenergic receptor. On 
the other hand, insulin remains the most potent anti-
lipolytic hormone by activation of phosphodiesterase 3B 
through the PI3K/Akt pathway ( 6 ). Other hormones such 
as glucocorticoids, glucagon, thyroid hormone, growth 
hormone, natriuretic peptide, and   -melanocyte stimulat-
ing hormone have also been shown to stimulate lipolysis. 
For instance, glucocorticoids activate lipolysis by down-
regulating phosphodiesterase 3B and perilipin, and up-
regulating adipose triglyceride lipase (ATGL) ( 7 ). TNF-  , 
a cyto kine, downregulates perilipin thereby bringing about 
lipolysis. In addition to protein kinase A (PKA)-dependent 
lipolysis, other kinases such as ERK1/2 through the PKC/
MAPK pathway and AMP-activated protein kinase as well 
as cGMP-dependent kinase are also involved in regulating 
lipolysis ( 6, 8, 9 ). With new discoveries on the molecular 
mechanisms of lipolysis, some of the proteins involved in 
its metabolic pathway have been proposed as drug targets 
for metabolic disorders ( 10 ). 
 Secretin (Sct) is best known for its action in stimulating 
bicarbonate release from pancreatic ductal epithelial cells 
and has been thoroughly studied for its gastrointestinal 
functions ( 11, 12 ). More recently, the role of Sct as a neu-
roactive peptide has been substantiated ( 11, 13–15 ) and it 
has been found to regulate, at multiple levels, in osmo-
regulation ( 16–19 ). Although Sct has recently been shown 
to be an anorectic peptide ( 20, 21 ), its metabolic role in 
regulating lipolysis remains a controversial issue. There is 
evidence supporting ( 22–25 ) and some negating ( 26–28 ) 
the lipolytic effects of Sct. Besides, there was no information 
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 Lipolysis is a tightly regulated process involving enzy-
matic hydrolysis of stored triacylglycerol in adipocytes in 
response to physiological demands for maintaining body 
energy homeostasis. During times of energy depletion, li-
polysis provides the needed free fatty acids (FFAs) as fuel 
for ATP production ( 1 ). For example, the energy for the 
continuous contractile activity of the heart muscle is met 
by the   -oxidation of long-chain FAs ( 2 ). FAs that are re-
leased from lipolysis are also involved in heat production 
through   -oxidation and mitochondrial uncoupling, lead-
ing to adaptive thermogenesis in brown adipose tissue ( 3 ). 
Dysregulation of lipolysis, such as impaired responsiveness 
to stimulated lipolysis and elevated circulating FFA levels 
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fat pads from Wt, SctR   /   , and Sct   /   mice were placed in Krebs-
Ringer bicarbonate buffer with 30 mM HEPES (KRBH buffer) 
supplemented with 3% FA-free BSA, 500 nmol/l adenosine, and 
1 mg/ml collagenase type I (Worthington Biochemical, Lake-
wood, NJ) and agitated for 60 min at 37°C. The cells were washed 
three times and then resuspended in KRBH buffer with 3% FA-
free BSA. Suspended adipocytes (10 5 cells/ml) were used for a 
lipolysis assay by incubating them with or without Sct (1 pM to 1 
  M) in the presence or absence of a nonselective   -adrenergic 
agonist, isoproterenol (Iso) (1   M) or   3 -AR-specifi c agonist CL-
316243 (5   M). After 60 min, glycerol release was measured with 
a kit from BioAssay Systems. For pathway analysis, cells were pre-
treated with 10   M H-89 (PKA inhibitor), 1   M R0-31-8220 (PKC 
inhibitor), 10   M SP 600125 (JNK inhibitor), or 10   M or 1   M 
CAY (HSL inhibitor) in the presence or absence of 1   M Sct. For 
time-dependent effects, cells were treated with or without 1   M 
Sct, and glycerol release was measured 0, 10, 20, 30, 40, 50, 60, 
and 90 min after stimulation. 
 Serum analysis 
 For in vivo lipolysis assay, baseline serum samples were col-
lected from 18 h-fasted Wt, SctR   /   , and Sct   /   mice by blood 
drawn from the tail vein. These mice were then treated with an 
intra-peritoneal (ip) injection of either Sct (0.5 mg/kg) or CL-
316243 (0.1 mg/kg), and serum samples were collected after 15 
min. For time point analysis, serum was collected at 5, 10, 15, 20, 
30, and 45 min after ip injection of Sct (0.5 mg/kg). FFA levels 
were determined by using a kit from BioAssay Systems. 
 PKA assay 
 A PepTag PKA activity assay kit (Promega) was used. Mice were 
fasted for 18 h and ip injected with either PBS or Sct (0.5 mg/
kg). Fifteen minutes after ip injection, epididymal fat pads were 
removed and processed as per the manufacturer’s instructions. 
 Quantitative real-time PCR 
 Total RNA from epididymal fat tissue was extracted using Tri-
zol reagent (Invitrogen). Total RNA (1   g) was used for the syn-
thesis of fi rst strand cDNA. The cDNA was diluted 3-fold and 
real-time PCR was performed either with specifi c TaqMan probes 
(GAPDH, 4352339E; SctR, Mm01290790_m1) or with a SYBR 
PCR Master Mix kit (Applied Biosystems) and primers (sequences 
listed in  Table 1 ). The specifi city of the SYBR Green PCR signal 
measured by the 7300 real-time PCR system (Applied Biosystems) 
was confi rmed by melting curve analysis and agarose gel electro-
phoresis. The threshold cycle ( C t ) value was used for calculating 
the ratio change in the target gene relative to the GAPDH con-
trol gene which was determined by the 2      Ct method ( 31 ). 
 Western blot analysis 
 Mice were treated with an ip injection of either PBS or Sct (0.5 
mg/kg) and 15 min later epididymal fat depots (100 mg) were 
as yet on the underlying cellular mechanism, secondary 
messenger pathway, and mode of action on the actions of 
Sct on adipocytes. In this report, using secretin receptor 
knockout (SctR   /   ) and secretin knockout (Sct   /   ) mice 
as controls in comparison with wild-type (Wt) animals, we 
sought to study the function of Sct in lipolysis and investi-
gate the molecular mechanisms involved in this process in 
mouse adipocytes. 
 MATERIALS AND METHODS 
 Reagents 
 Antibodies for hormone sensitive lipase (HSL), HSL-660 ser , 
HSL-563 ser , HSL-565 ser , perilipin, ATGL, and GAPDH were pur-
chased from Cell Signaling Technology (Beverly, MA); the anti-
body for ABDH5 was from Abcam (Cambridge, MA), G0S2 from 
LifeSpan BioSciences (Seattle, WA), and perilipin-522 ser from Vala 
Sciences (San Diego, CA). The   3 -specifi c adrenergic receptor 
(  3 -AR) agonist, CL-316243, was from Sigma (St. Louis, MO). HSL 
inhibitor CAY10499 (CAY) was from Cayman Chemical (Ann 
Arbor, MI). The enzyme immunoassay (EIA) kit for Sct was pur-
chased from Phoenix Pharmaceuticals, Inc . (Burlingame, CA). 
Glycerol and FFA kits were from BioAssay Systems (Hayward, 
CA). Other reagents were from Sigma (St. Louis, MO). 
 Animals 
 Procedures of animal care and handling were in accordance 
with the protocols approved by the Committee on the Use of Live 
Animals in Teaching and Research of the University of Hong 
Kong. All experiments were carried out using adult mice (23–26 
g) of at least N5 generation, which were kept in a temperature-
controlled room with a 12 h light-dark cycle. Mice were fed ad 
libitum with standard rodent chow (#5010; Test Diet, Richmond, 
IN) and water unless otherwise stated. 
 Fasting experiments 
 Age- and weight-matched mice (8–9 weeks old) were used for 
all the experiments. Food was removed from a cohort of mice at 
the beginning of the dark cycle and epididymal fat pads were col-
lected from fasted and control mice at 0, 12, 18, and 24 h, and 
were immediately snap-frozen with liquid nitrogen for real-time 
quantitative measurements of secretin receptor (SctR) tran-
scripts. Blood was collected from mice at the same time points 
and plasma Sct concentrations were measured by enzyme immu-
noassays (Phoenix Pharmaceuticals Inc.). 
 Adipocyte isolation and in vitro lipolysis assay 
 Adipocyte isolation and in vitro lipolysis assay were done as 
described ( 29, 30 ), with minor modifi cations. Briefl y, epididymal 
 TABLE 1. Sequence of the oligonucleotides used for real time PCR 
Primer Sequence 5 ′  → 3 ′ 
HSL CAACATGGCATCAACCACTGGCCTGGGATCAGAGGTGATG
ATGL TGTGGCCTCATTCCTCCTACTCGTGGATGTTGGTGGAGCT
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CA) as described ( 16 ). Blood samples were collected from the tail 
vein at 0, 18, and 24 h for measurements of FFAs (BioAssay Systems). 
Epididymal fat pads were removed after 24 h and snap-frozen in 
liquid nitrogen for subsequent real-time PCR analysis. 
 Immunofl uorescence imaging and immunohistochemical 
staining 
 Immunocytochemical staining was performed as described 
( 34 ) with minor modifi cations. Isolated adipocytes were treated 
subsequently homogenized in a buffer composed of 25 mM Tris-
HCl (pH 7.4), 25 mM NaCl, 1 mM MgCl 2 , 2.7 mM KCl, and pro-
tease and phosphatase inhibitors (0.5 mM Na 3 VO 4 , 1 mM NaF, 
1   M leupeptin, 1   M pepstatin, 1   M okadaic acid, and 0.1 mM 
PMSF). For isolated adipocytes, cells were stimulated with or 
without Sct (1   M) or Iso (1   M) for 30 min before being lysed 
with buffer as described above. Western blot analysis of the lysates 
was performed as described ( 32 ) with dilutions of primary anti-
bodies as suggested by their respective companies. 
 Continuous Sct infusion 
 Adult male mice (8–9 weeks old) were treated with PBS or Sct 
[2.5 nmol/kg/day, a dose similar to that published previously ( 33 )] 
by ip implantation of Alzet ® osmotic minipumps (Alzet, Cupertino, 
 Fig.  1. Increases of both the Sct peptide level in circulation and 
the SctR transcript level in epididymal fat tissue during starvation. 
Mice were starved and blood samples or fat tissues were obtained for 
measurements of Sct peptide and SctR transcript levels, respectively, 
at specifi ed hours. A: Sct peptide concentrations in the circulation 
measured by an EIA kit were found to be signifi cantly increased after 
starvation . B: SctR transcript levels measured by real-time PCR were 
found to be signifi cantly increased after starvation. For (A) and (B), 
n = 9–11 (* P < 0.05, ** P < 0.0005 versus 0 h): C: SctR protein was 
localized on the adipose cell membrane of Wt mice by immunohis-
tochemical staining using SctR   /   mice as negative controls. 
 Fig.  2. Sct via SctR stimulates lipolysis in dose- and time-depen-
dant manners. A: Glycerol release is increased in the presence of 
graded concentrations of Sct treatment for 1 h in Wt and Sct   /   
adipocytes but not in SctR   /   adipocytes, indicating specifi cities of 
the lipolytic actions of Sct. B: Sct (1   M) stimulates glycerol release 
time-dependently in Wt adipocytes. C: Adipocytes from Wt, Sct   /   , 
and SctR   /   mice were found to exhibit similar basal lipolytic ac-
tivities and responded similarly to 1   M Iso or 5   M CL-316243 
treatment for 1 h. Data are means ± SEM of three separate experi-
ments performed in triplicate. * P < 0.0001. 
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Bannockburn, IL) according to the recommended procedure us-
ing a rabbit anti-mouse SctR antibody [1:300; raised in our labo-
ratory using a synthetic peptide (R-A-E-C-L-R-E-L-S-E-E-K-K) that 
is present in the mouse SctR] ( 17, 35 ). 
 Statistical analysis 
 All data are shown as means ± SE. The deviations between 
groups were analyzed using Prism 3.0 software (GraphPad Soft-
ware Inc., San Diego, CA). An unpaired  t -test was performed 
when two groups were under consideration, whereas data from 
>2 groups were analyzed by one-way ANOVA, followed by Dun-
nett’s test. 
with or without 1   M Sct or 1   M Iso for 20 min, fi xed, and then 
blocked for 1 h in 5% goat serum at room temperature. Cells 
were then incubated overnight at 4°C with the primary antibody, 
anti-HSL (Cell Signaling Technology) (1:50 dilution). This was 
followed by a wash and 1 h incubation at room temperature with 
Alexa Fluor 488 goat anti-rabbit secondary antibody (1:300 dilu-
tion; Molecular Probes). After washing, the cells were placed in 
SlowFade Gold antifade reagent (Invitrogen) and confocal im-
ages were obtained using a Carl Zeiss LSM 710-NLO (Carl Zeiss, 
Oberkochen, Germany). For immunohistochemical staining, 
epididymal adipose tissue was fi xed in 3.7% formalin, embedded 
in paraffi n, and sectioned (7   m). Immunostaining was per-
formed with a Leica Bond-Max automatic immunostainer (Leica, 
 Fig.  3. Lipolytic actions of Sct are mediated by PKA and by phosphorylation of 660 ser and 563 ser of HSL in 
vitro. A: Isolated adipocytes were treated with 10   M H-89 (PKA inhibitor), 1   M Ro-31-8220 (PKC inhibi-
tor), 10   M SP 600125 (JNK inhibitor), or 10   M or 1   M CAY (HSL inhibitor) before stimulation with 1 
  M Sct for 1 h. Lipolysis by Sct in Wt and Sct   /   adipocytes was completely abrogated by H-89, but no effects 
were observed for Ro-31-8220 and SP 600125. SctR   /   serves as the negative control. Data are means ± SEM 
of three separate experiments performed in triplicate. * P < 0.0001 from basal. B: Small amounts of FFA re-
lease are still observed in adipose cells incubated with 10   M or 1   M CAY (HSL inhibitor) along with 1   M 
Sct for 1 h. ** P < 0.0001, * P < 0.001 from basal. C: Isolated adipocytes incubated with 1   M Sct for 1 h were 
used for Western analysis. Sct phosphorylates HSL at 660 ser and 563 ser , but not at 565 ser , and phosphorylates 
perilipin at 522 ser while total HSL, ATGL, G0S2, ABDH5, perilipin, and GAPDH proteins remain unaltered 
by Sct. The left-hand chart represents fold changes compared with control by densitometric analysis. Data 
are means ± SEM of three separate experiments performed in duplicate. * P < 0.05 from control. 
 Fig.  4. Sct stimulates translocation of HSL from cytosol to lipid droplet. Isolated adipocytes from Wt or 
SctR   /   mice were stimulated with or without 1   M Sct or 1   M Iso (positive control). Cells were fi xed and 
translocation of HSL from the cytosol to lipid droplet was visualized by confocal microscopy using an anti-
HSL antibody (1:50 dilution) and subsequent incubation with Alexa-488 sary antibodies (1:300 dilution). 
Red arrows in the fi gure denote the translocation process. BF, bright fi eld. 
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 RESULTS 
 Sct level in circulation and SctR expression in epididymal 
adipose tissue are increased during starvation 
 To determine whether Sct plays a physiological role in 
lipid mobilization, we fi rst studied the effects of fasting on 
the Sct level in the circulation and SctR expression in the 
epididymal adipose tissue of mice. Interestingly, we found 
that the Sct level in the circulation ( Fig. 1A ) and SctR ( Fig. 1B ) 
transcript in the adipose tissue increased in a time-depen-
dent manner, and the most signifi cant increases were ob-
served after 18 h fasting (3.2 ± 1.1-fold and 9.4 ± 1.6-fold 
increase in Sct peptide in blood and SctR transcript in adi-
pose tissue, respectively). Expression of SctR protein in 
the adipocyte cell membrane was confi rmed by immuno-
histochemical staining ( Fig. 1C ) using the same tissue 
from SctR   /   mice as a negative control. In summary, the 
increase of both the ligand in the circulation and the re-
ceptor in the fat tissue suggests potential activity of Sct in 
fat metabolism in response to starvation. 
 Sct stimulates lipolysis in isolated adipocytes from mice 
via SctR and PKA 
 To determine whether Sct stimulates lipolysis, we investi-
gated the in vitro rate of lipolysis in the presence of graded 
concentrations of Sct in isolated adipocytes in Wt mice, us-
ing SctR   /   and Sct   /   as negative and positive controls, 
respectively. In this study, the rate of glycerol release from 
isolated adipocytes into the culture medium was determined 
to refl ect its lipolytic activity. Sct was able to stimulate a dose-
dependent release of glycerol in Wt adipocytes ( Fig. 2A ) 
with an EC 50 of 37.5 nM. This lipolytic response of Sct was 
found to be specifi c to its receptor, as this effect was com-
pletely abolished in SctR   /   adipocytes ( Fig. 2A ), but could 
be reproduced in Sct   /   adipocytes ( Fig. 2A ). Sct also stim-
ulated lipolysis in Wt adipocytes in a time-dependent man-
ner ( Fig. 2B ). Isolated adipocytes from Wt, Sct   /   , and 
SctR   /   mice had similar basal lipolytic activity (glycerol re-
lease in   mol/10 5 cells/h), as well as no signifi cant differ-
ences in their lipolytic responses to 1   M Iso (a nonselective 
  -adrenergic agonist) or 5   M CL-316243 (  3 -AR-specifi c 
agonist) ( Fig. 2C ), indicating that SctR   /   adipocytes are 
able to respond normally to other lipolytic agents. 
 After showing the lipolytic actions of Sct, we next investi-
gated its secondary messenger pathway. In this study, the 
specifi c inhibitor of PKA (10   M H-89), PKC (1   M Ro-31-
8220), or JNK (10   M SP 600125) was preincubated with 
adipocytes before stimulation by 1   M Sct; it was found that 
only H-89, but not R0-31-8220 or SP 600125, could com-
pletely abolish lipolytic actions of Sct in Wt and Sct   /   adi-
pocytes ( Fig. 3A ). The rates of glycerol release in SctR   /   
adipocytes were similar to basal levels in all treatment groups 
due to the lack of SctR in these cells. Taken together, our 
data show that the lipolytic effect of Sct is mediated by the 
PKA pathway. Additionally, incubation with the HSL spe-
cifi c inhibitor, 10   M or 1   M CAY, completely abolished 
the glycerol release stimulated by 1   M Sct ( Fig. 3A ). Fur-
thermore, FFA release by 1   M Sct was attenuated to around 
33–35% on coincubation with 10   M or 1   M CAY ( Fig. 3B ). 
Such a response is similar to that of catecholamine in HSL-
null mouse adipocytes, wherein catecholamine stimulation 
completely abolished glycerol release and severely reduced 
FFA release ( 36, 37 ). This study suggests that HSL is the 
primary downstream enzyme involved, while delineating 
the role for other enzymes to be minimal or none. 
 Sct activates phosphorylation of 660 ser and 563 ser in HSL 
and translocation of HSL from cytosol to lipid 
droplets in adipocytes 
 To confi rm the involvement of HSL as a downstream regu-
lator, we measured changes in the phosphorylation of the 
serine residues at positions 660, 563, and 565 of HSL after Sct 
 Fig.  5. Sct stimulates an acute FFA release in vivo through SctR. 
Stimulation of lipolysis by Sct was detected by measuring changes 
in the levels of FFAs in circulation after ip injection of Sct. Blood 
was collected from the tail vein for measurement of FFAs. A: Sct 
(0.5 mg/kg, ip) induced an acute lipolytic response in Wt mice 
(n = 9) up to 15 min after injection. * P < 0.05. B: The same dose of 
ip Sct signifi cantly augments FFA concentrations in Wt (n = 8) and 
Sct   /   (n = 9) mice, but not in SctR   /   (n = 7) mice. * P < 0.0005, 
** P < 0.0001 from control. C: CL-316243 (0.1 mg/kg), a   3 -AR ago-
nist, had similar effects in Wt and SctR   /   mice (n = 8 each). * P < 
0.005 from control. 
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 Sct induces an acute lipolytic response through SctR and 
PKA in vivo 
 After showing the in vitro lipolytic actions of Sct 
through PKA and HSL in isolated adipocytes, our next 
objective was to investigate whether Sct could induce li-
polysis in vivo. After 5, 10, and 15 min ip injections of Sct 
(0.5 mg/kg), we found signifi cant elevation of circulat-
ing FFAs in the blood ( Fig. 5A ). This lipolytic effect of Sct 
is specifi c to SctR because the rise in the FFA level was 
not observed in SctR   /   , while it could be reproduced in 
Sct   /   mice ( Fig. 5B ). In addition, both the Wt and 
SctR   /   mice showed a normal lipolytic response to ip 
CL-316243 (0.1 mg/kg) as controls ( Fig. 5C ), indicating 
the normal functioning of these animals in response to 
the   3 -AR-specifi c agonist. 
 To test the in vivo involvement of PKA and HSL in car-
rying out the lipolytic effects of Sct, mice were ip injected 
with Sct (0.5 mg/kg) or control PBS, and epididymal adi-
pose tissue was removed 15 min after for PKA measure-
ments. It was found that PKA activity in epididymal adipose 
tissue was signifi cantly upregulated in Sct-injected mice 
when compared with control mice ( Fig. 6A ). Similar to the 
in vitro studies, Sct injection resulted in increased phos-
phorylation of 660 ser in HSL ( Fig. 6B ), while there were no 
signifi cant changes in the phosphorylation status of 563 ser 
and 565 ser , as well as protein levels of HSL. In summary, 
our in vivo data confi rm that Sct activates lipolysis through 
PKA to stimulate phosphorylation of HSL-660 ser . 
stimulation. While the protein levels of GAPDH and total 
HSL of the Wt adipocytes were similar with or without Sct 
stimulation ( Fig. 3C ), Sct incubation led to a 4.26 ± 0.75-fold 
( P < 0.05) and a 1.99 ± 0.32-fold ( P < 0.05) increase in phos-
phorylation at positions 660 and 563, respectively, but not 
Ser 565 ( Fig. 3C ). Perilipin phosphorylation is essential for 
HSL-stimulated lipolysis, and Sct consistently stimulated 
phosphorylation of perilipin ( Fig. 3C ). Additionally, stimula-
tion with Sct did not have any effect on the triglyceride lipase, 
ATGL, and its positive and negative regulators ABDH5 and 
G0S2, respectively ( Fig. 3C ), thus confi rming that HSL is the 
primary enzyme involved in the lipolytic effect of Sct. In sum-
mary, our fi ndings suggest that Sct-activated lipolysis in adi-
pocytes could be mediated by the phosphorylation of HSL at 
660 ser and 563 ser . 
 To understand further the cellular mechanism of Sct on 
lipolysis, translocation of HSL from the cytosol to the lipid 
droplet in isolated adipocytes was studied. Through im-
munofl uorescent imaging, in the positive control, treat-
ment of isolated adipocytes with Iso clearly resulted in the 
translocation of HSL from the cytosol to the phospholipid 
monolayer surface of the lipid droplet in Wt and SctR adi-
pocytes ( Fig. 4 ). This translocation of HSL was also ob-
served in Sct-treated Wt cells, but not in Sct-treated SctR   /   
adipocytes or in unstimulated Wt and SctR   /   cells ( Fig. 4 ). 
Our fi ndings suggest that the lipolytic action of Sct is me-
diated via the translocation of HSL from the cytosol to the 
lipid droplet. 
 Fig.  6. In vivo Sct activates PKA and phosphorylates HSL at serine residue 660 ser . Mice were ip injected with 
Sct (0.5 mg/kg in PBS) or PBS, and epididymal adipose tissue was collected 15 min after injection for PKA 
assay and Western blotting. A: Sct stimulates PKA activity; the left-hand panel represents spectophotometric 
measurements of the bands. * P < 0.05. B: Sct stimulates phosphorylation of HSL-660 ser and does not affect 
the protein levels of HSL-563 ser , HSL-565 ser , and total HSL. The left-hand chart represents fold changes com-
pared with control by densitometric analysis. Data are means ± SEM of three separate experiments per-
formed in duplicate. * P < 0.05. 












Supplemental Material can be found at:
Secretin stimulates PKA and HSL mediated lipolysis Q1 197
involved in fasting-induced lipolysis, while glucocorticoids 
have also been shown to play a role ( 6 ). Among hormones 
that stimulate lipolysis, such as catecholamines, insulin, 
glucagon, growth hormone, and thyroid hormone ( 5, 6 ), 
the lipolytic effect of Sct remains elusive ( 23–28 ). Being a 
recently recognized anorectic hormone ( 20 ) with ele-
vated plasma concentrations during fasting, as shown in 
our study and other studies ( 38–40 ), along with increased 
SctR expression in the epididymal adipose tissue during 
fasting ( Fig. 1B ), we therefore hypothesized the potential 
function of Sct in lipid metabolism. Consistent with this 
hypothesis, using Sct   /   and SctR   /   mouse models, we 
show here that Sct is able to stimulate dose- and time-
dependent lipolysis in both in vitro adipocytes and in in 
vivo animals. This lipolytic effect is mediated by SctR 
expressed on the fat cells, which stimulates the cAMP-
dependent protein kinase, PKA, which leads to phospho-
rylation of HSL, the rate-limiting enzyme for lipolysis ( 41 ), 
to bring about translocation of HSL to fat droplets for the 
activation lipolysis ( Fig. 8 ). PKA is known to phosphorylate 
HSL at residues 565 ser , 563 ser , 660 ser , and 659 ser ; where 
565 ser is considered the basal phosphorylation site, while 
the other three serines are regulatory sites. Among them, 
 Continuous Sct infusion does not increase circulating 
FFA levels 
 Our in vivo and in vitro data consistently showed an 
acute lipolytic effect of Sct, therefore we sought to investi-
gate its long-term effect on lipid metabolism by continu-
ous infusion of Sct (2.5 nmol/kg/day) with a mini-osmotic 
pump. Sct infusion for 18 to 24 h was found to be unable 
to signifi cantly change levels of circulating FFAs ( Fig. 7A ). 
When we measured expression changes of lipogenic and 
lipolytic genes, interestingly, a 24 h Sct infusion was found 
to elevate both lipolytic HSL as well as lipogenic gene clus-
ter of differentiation 36 (CD 36) transcript levels ( Fig. 7B ). 
These data suggest a dual lipolytic and lipogenic role of 
long-term infusion of Sct that needs to be explored and 
clarifi ed in future studies. 
 DISCUSSION 
 Catabolizing triacylglycerols stored in lipid droplets is a 
simple biochemical reaction; the process, however, is 
highly regulated and required for energy homeostasis 
( 4–6 ). Catecholamine is known, so far, to be the key hormone 
 Fig.  7. Continuous infusion of Sct does not increase circulating FFA levels. Mice (n = 5–6) that were fed ad 
libitum were infused with Sct at a concentration of 2.5 nmol/kg/day ip continuously through a mini-osmotic 
pump. A: Circulating FFA levels did not change signifi cantly after continuous infusion of Sct. B: Transcript 
levels of a lipolytic gene (HSL) and a lipogenic gene (CD 36) were increased after continuous Sct infusion 
for 24 h. * P < 0.05, ** P < 0.0005 from control. 
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phosphorylation at 660 ser was shown to be important for 
lipolysis because mutation of this residue resulted in a loss 
of enzymatic activity ( 42, 43 ). Consistent with this, we show 
that Sct is able to stimulate phosphorylation of HSL-660 ser in 
both in vitro and in vivo studies. Similar to catecholamines 
( 42 ) and glucagon ( 44 ) that act via the PKA/HSL pathway 
to promote translocation of HSL from the cytosol to the 
phospholipid monolayer of the lipid droplet, we were also 
able to observe an accumulation of HSL surrounding the 
lipid droplet after Sct stimulation in Wt, but not in SctR   /   , 
adipocytes . It seems that catecholamines, glucagon, and 
Sct use the same intracellular pathway to stimulate lipoly-
sis in the fat cells. A working model summarizing the mo-
lecular mechanism in the lipolytic effect of Sct is shown in 
 Fig. 8 . 
 While catecholamines are mainly responsible for acute 
lipolysis, other stimulants such as TNF-  and glucocorti-
coids have more chronic lipolytic effects ( 45 ). As shown in 
this study, Sct is able to stimulate an acute lipolytic re-
sponse in vivo, evidenced by an increase in circulating FFA 
levels upon Sct injection ( Fig. 5A ). A 24 h continuous infu-
sion of Sct through a mini-osmotic pump had no signifi cant 
effect on levels of circulating FFAs, but could stimulate ex-
pressions of lipolytic HSL and lipogenic CD 36 genes, sug-
gesting that effects of long-term Sct on lipid metabolism is 
different from its acute response. In fact, it has been re-
ported that chronic elevated levels of Sct can increase FA 
uptake and triglyceride storage in fat cells, as well as up-
regulation of FA uptake genes including CD 36 in adipose 
cells in vitro ( 25 ). In addition, the expression of SctR has 
been found to be increased in the omental adipose tissue 
of obese individuals ( 46 ) and has been positively corre-
lated with body mass index ( 25 ). This evidence, along with 
our fi ndings, suggests a potential lipogenic role for long-
term Sct, although this remains to be confi rmed and the 
molecular mechanisms elucidated in future. 
 The balance between triacylglycerol hydrolysis and FFA 
esterifi cation controls lipid homeostasis in our body. A 
slight alteration in these processes could therefore lead to 
metabolic disorders such as type 2 diabetes ( 47 ), hepatic 
steatosis ( 48 ), cardiovascular diseases ( 49 ), lipotoxicity 
( 50 ), dyslipidemia ( 51 ), and certain types of cancer ( 52 ). 
In the case of obesity, higher levels of FFAs in the circulation 
due to changes in lipolytic rates result in the development 
 Fig.  8. Working model summarizing the lipolytic effect of Sct. Sct binds SctR on the plasma membrane of adipocytes to activate the 
cAMP-dependent PKA. PKA then phosphorylates HSL at 660 ser leading to translocation of HSL from the cytosol to the phospholipid mono-
layer of the lipid droplet. The translocated HSL is responsible for the hydrolysis of stored triacylglycerol to release glycerol and FFAs. 
Norepinephrine (a catecholamine) and glucagon both activate the PKA pathway similar to Sct. TNF-  and glucocorticoids stimulate lipoly-
sis by downregulating perilipin and enhancing the expression of ATGL, respectively. Insulin inhibits lipolysis by reducing the cAMP level 
through activation of PDE via the PI3K/Akt pathway. AMPK, AMP-activated protein kinase. 
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of insulin resistance ( 53 ). In familial hyperlipidemia, de-
creased expression or function of HSL causes an impaired 
lipolytic function of catecholamines ( 54 ). It is therefore 
not surprising that proteins involved in lipid metabolism 
are targeted as pharmacological strategies against disor-
ders such as obesity and metabolic syndrome ( 10, 55 ). 
This reinforces the relevance and importance of the need 
for more research on Sct and lipid metabolism. Our 
group and others have recently highlighted the impor-
tance of reevaluating the metabolic effects of Sct ( 20, 56 ). 
In this report, we have provided evidence to conclude 
that Sct has an acute lipolytic effect in vitro and in vivo . 
The relationship between lipid metabolism and Sct 
should warrant further studies in the future to provide an 
alternative therapeutic means to tackle various metabolic 
diseases.  
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